| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 295.321 | 194.998 | 433.083 | 533.311 | 734.750 | 162.981 |
| Total Income - EUR | - | - | - | - | 295.364 | 195.867 | 433.084 | 533.311 | 756.854 | 162.981 |
| Total Expenses - EUR | - | - | - | - | 271.747 | 166.545 | 358.138 | 406.201 | 660.562 | 154.769 |
| Gross Profit/Loss - EUR | - | - | - | - | 23.617 | 29.322 | 74.946 | 127.110 | 96.292 | 8.212 |
| Net Profit/Loss - EUR | - | - | - | - | 20.524 | 27.337 | 71.065 | 121.796 | 54.524 | 6.925 |
| Employees | - | - | - | - | 3 | 2 | 3 | 5 | 0 | 0 |
Check the financial reports for the company - Gsk Real Jupiter S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 0 | 3.716 | 0 | 0 |
| Current Assets | - | - | - | - | 21.279 | 53.237 | 92.231 | 150.542 | 66.074 | 435.764 |
| Inventories | - | - | - | - | 1.017 | 9.295 | 20.400 | 37.767 | 0 | 10.588 |
| Receivables | - | - | - | - | 1.550 | 62 | 1.025 | 3.190 | 66.074 | 330.287 |
| Cash | - | - | - | - | 18.712 | 43.880 | 70.806 | 109.585 | 0 | 94.889 |
| Shareholders Funds | - | - | - | - | 20.566 | 47.513 | 71.114 | 136.352 | 54.573 | 61.193 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 713 | 5.724 | 21.117 | 17.906 | 11.501 | 213.641 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 160.930 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4631 - 4631" | |||||||||
| CAEN Financial Year |
4639
|
|||||||||
Comments - Gsk Real Jupiter S.r.l.